Orexo strengthens the commercial leadership structure and appoints Nikolaj Sørensen as new CEO and Martin Nicklasson as Executive Chairman
Uppsala, Sweden – February 5, 2013 - Orexo AB today announced the transition of its CEO, as the company prepares for the anticipated US commercialization of its products, Zubsolv™ and Abstral®. Nikolaj Sørensen, currently Chief Commercial Officer of Orexo, will be promoted to CEO of the company and Martin Nicklasson, currently Chairman of the Board, will be appointed Executive Chairman, both effective as of today. Nikolaj Sørensen will succeed Anders Lundström, who will step down as CEO of the company after successful two year tenure. During Anders Lundström’s engagement Orexo has